Physician profile
Paige E Bowman
NPI 1710339239
$816.32
in general payments reported to CMS, 2019-2025
19 companies · $391 in 2025
The $391 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $105 · 2024: $321 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $816.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $259.64 | 2023-2025 | Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $148.08 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $62.40 | 2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $58.82 | 2023-2024 | Mounjaro |
| Supernus Pharmaceuticals, INC. | $47.94 | 2025 | Qelbree |
| Corium, LLC | $28.97 | 2023-2024 | Azstarys |
| Boston Scientific Corporation | $25.17 | 2024 | Watchman Flx |
| Glaxosmithkline, LLC. | $18.91 | 2025 | Trelegy Ellipta |
| Astellas Pharma US INC | $18.69 | 2025 | Veozah |
| Pfizer INC. | $17.59 | 2025 | |
| Cranial Technologies, INC | $17.30 | 2025 | Doc Band |
| Teva Pharmaceuticals USA, INC. | $17.14 | 2025 | Austedo Xr |
| Axsome Therapeutics, INC. | $16.94 | 2025 | Auvelity |
| Exeltis, USA INC. | $16.20 | 2023 | Slynd |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.69 | 2024 | Xifaxan |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $14.83 | 2025 | Repatha, Otezla |
| Amneal Pharmaceuticals LLC | $14.14 | 2024 | Unithroid |
| Cequr Corporation | $13.18 | 2024 | Cequr Simplicity |
| Phathom Pharmaceuticals, INC. | $4.69 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paige Bowman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.